Search
forLearn
5 / 801 resultslearn Pyrilutamide
highly targeted anti-androgen that might have minimal systemic effects
learn Setipiprant
learn RU58841
a potent but unapproved and potentially problematic topical anti-androgen
learn Tofacitinib
a JAK inhibitor for alopecia areata and other autoimmune conditions
Research
5 / 209 results
research Sacituzumab tirumotecan (sac-TMT/MK-2870/SKB264): a novel antibody–drug conjugate in breast cancer
Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.
research Cancer Treatments and Alopecia: A Systematic Review
Cancer treatments often cause hair loss, and more research is needed to prevent and treat it.
research Topoisomerase‐Interacting Agents
Topoisomerase inhibitors can cause hair loss, skin rash, hand-foot syndrome, and nail changes.
research Safety profile of CAP7.1 obtained during Phase I Trial in adult patients with refractory malignancies
CAP7.1 is generally safe at 200 mg/m²/day, but can cause fatigue, nausea, hair loss, fever, and blood-related issues.
research Clinical Development of Topoisomerase-Interactive Drugs
New drugs targeting DNA enzymes show promise for cancer treatment but have side effects like immune system suppression and hair loss.
Community Join
5 / 1000+ resultscommunity Kintor Pharma Announces Positive Top-line U.S. Phase I Trial Results of GT20029, the World’s First Topical Use PROTAC Compound
The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.
community Anagenic is trying to compound Gt20029
The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.
community GT20029. Kintor Pharma’s Product
The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.
community Pyrilutamide cease and desist from Kintor
Considering a hair transplant, using Pyrilutamide, the potential availability of CosmeRNA, and the significance of taking Minoxidil and Finasteride for long-term results.
community Kintor develop GT20026 Anti-Androgen receptor drug with NO SIDES
The conversation discusses GT20029, a new topical drug for hair loss and acne without notable side effects, which has been accepted for investigational use in China. Some users express skepticism about the legitimacy of the company and the potential for other drugs like RU58841 to be developed due to patent expiration and lack of profitability.